F unctional abdominal pain (FAP) is common among children and adolescents, with a prevalence between 0.3% and 19%. 1 FAP is associated with comorbid somatic symptoms and frequent medical visits. 1 FAP in childhood may predict future morbidity; longitudinal studies have shown that children with FAP are at increased risk for functional gastrointestinal disorders (FGIDs), anxiety, and depression in young adulthood. 2, 3 Nausea is a common somatic symptom among pediatric FAP patients-more than a quarter experience nausea daily, and half experience nausea at least twice a week. [4] [5] [6] Despite the absence of an identifiable organic etiology, nausea in FAP patients has been associated with higher levels of disability, negative affect, fatigue, and anxiety. 4, [6] [7] [8] [9] Currently, there are no empirically supported interventions for pediatric functional nausea. 7 Studies have not assessed the impact of nausea prospectively in pediatric FAP patients. Thus, it is unknown whether comorbid nausea increases the risk for poor health outcomes.
The goal of our study was to evaluate the long-term physical and mental health outcomes of pediatric FAP patients reporting clinically significant nausea. We hypothesized that pediatric patients with FAP and nausea (FAP þ nausea), compared with pediatric patients with FAP and no nausea (FAP only), would report more somatic and internalizing symptoms both at baseline and at a 9-year follow-up evaluation. In addition, we hypothesized that the FAP þ nausea group, compared with the FAP-only group, would be more likely to meet the criteria for a FGID in late adolescence and young adulthood, indicating an increased risk for persistence of FAP.
Methods

Patients
Baseline evaluation. Data were drawn from a larger prospective study of health outcomes in consecutive new patients (age, 8-17 y) evaluated for FAP (duration, >3 mo) in a pediatric gastroenterology clinic. Patients were enrolled in Institutional Review Board-approved studies conducted by Walker et al between 1993 and 2004. 2, 3, [10] [11] [12] [13] Patients underwent medical evaluation for abdominal pain and were eligible if they had no significant organic etiology for their pain. Patients with minor histologic findings of esophagitis and normal endoscopy were not excluded because histologic findings alone are not sensitive or specific for organic disease.
14 Additional eligibility criteria included the following: living with parent(s) or a parent figure, capable of consent/assent, and no chronic illness or developmental delay. The baseline sample comprised 871 pediatric FAP patients (60% female; 92%% Caucasian; mean age, 11.61 AE 2.4 y). Patients and parents provided informed consent/assent and completed questionnaires in the clinic at the time of initial evaluation.
Follow-up evaluation. Patients who agreed to followup evaluation were contacted by mail or telephone. Eligibility criteria for the follow-up study included age 12 years or older at follow-up evaluation, a minimum of 4 years between the initial evaluation and follow-up evaluation, and no current chronic or life-threatening disease. A total of 760 patients were eligible and 396 patients could be contacted and consented. Four patients were excluded because of incomplete data. Thus, the patient sample at follow-up evaluation comprised 392 pediatric FAP patients assessed at an average of 8.7 AE 3.3 years after the initial evaluation (65% female; 91% Caucasian; mean age, 20.8 AE 3.9 y). For the follow-up study, patients answered questions about their health and current symptoms by means of a telephone interview and online survey. A subset of these patients (n ¼ 336) completed a psychodiagnostic interview.
Measures
Gastrointestinal and nongastrointestinal symptoms. The Children's Somatization Inventory (CSI) assesses the severity of 35 somatic symptoms experienced during the past 2 weeks. 15, 16 Two subscales were calculated: gastrointestinal (GI) symptoms and non-GI symptoms. For this study, nausea was excluded from the GI symptom subscale. Patients rated how much they were bothered by each symptom during the past 2 weeks on a 5-point scale ranging from 0 (not at all) to 4 (a lot). For each subscale, item responses were summed, yielding scores ranging from 0 to 32 (GI symptoms) and 0 to 104 (non-GI symptoms). Patients completed the CSI at both baseline and follow-up evaluations.
Nausea. Patients were defined as having clinically significant nausea if they responded "a lot" or "a whole lot" to item 13 on the CSI ("nausea or upset stomach"). 15 Patients who reported experiencing nausea "not at all," "a little," or "some" were not considered to have clinically significant nausea.
Abdominal pain. The Abdominal Pain Index assesses the weekly frequency, daily frequency, duration, and typical intensity of abdominal pain during the past 2 weeks. 17 Patient responses are converted to a 5-point scale and averaged to yield a mean index score ranging from 0 to 4. Higher scores indicate more severe abdominal pain. Patients completed the Abdominal Pain Index at both baseline and follow-up evaluations.
Internalizing symptoms. Depressive symptoms. At baseline, patients completed the Children's Depression Inventory, 18 a validated self-report measure of depressive symptoms during the past 2 weeks. Responses are summed, yielding a total score between 0 and 54, with higher scores indicating higher levels of depressive symptoms.
At follow-up evaluation, patients completed the Center for Epidemiological Studies-Depression Scale, 19 Diagnostic criteria for anxiety and depressive disorders were assessed at follow-up evaluation with The Anxiety Disorders Interview Schedule-IV: Adult Lifetime and Child and Parent Versions, 21 a semistructured interview administered by a trained clinician and designed to assign both current and lifetime Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) psychiatric diagnoses. A clinical severity rating indicating at least moderate severity/impairment is required for assigning a diagnosis of an anxiety or depressive disorder. Further details on the administration of the diagnostic interviews are provided by Shelby et al. 2 Functional gastrointestinal disorders. The Rome III Diagnostic Questionnaire 22 is a self-report measure used to identify individuals who meet the Rome III symptom criteria for FGIDs. At follow-up evaluation, the 24 items assessing symptoms associated with abdominal painrelated FGIDs (irritable bowel syndrome, functional dyspepsia, abdominal migraine, and functional abdominal pain) were administered.
Data Analysis
Analyses were performed using SPSS Statistics, version 18 (SPSS, Inc, Chicago, IL). Descriptive analyses used chi-squared tests. Independent t tests compared continuous measures, with a 2-tailed P value less than .05 a criterion for significance. Because abdominal pain has shown a predictive relation to the long-term outcomes in our study, 11 we controlled for abdominal pain severity in subsequent analyses to examine the unique impact of nausea in FAP patients. Thus, 1-way analyses of covariance, controlling for baseline abdominal pain severity, examined group differences on continuous baseline and follow-up measures. Logistic regressions, controlling for abdominal pain severity, examined whether the FAP þ nausea group, compared with the FAP-only group, was at increased risk for psychiatric disorders and FGIDs at follow-up evaluation.
Results
Baseline Evaluation
At baseline, 391 (44.83%) pediatric patients had significant nausea. There were no differences in sex or race (Table 1) ; however, FAP þ nausea patients were slightly older at baseline than FAP-only patients (12.36 AE 2.53 vs 11.79 AE 2.43 y; P ¼ .001). FAP þ nausea patients reported significantly greater abdominal pain severity than FAP-only patients (t[871] ¼ -12.90; P < . 001). Abdominal pain severity was controlled for in subsequent analyses reported later to eliminate this difference as a confounding factor.
Controlling for abdominal pain severity, FAP þ nausea patients, compared with FAP-only patients, reported significantly more GI symptoms (F [1, 869] Table 2 .
Follow-Up Evaluation
Nausea at the initial evaluation significantly correlated with nausea at follow-up evaluation (r ¼ 0.226; P < .001). FAP þ nausea patients continued to report greater abdominal pain severity at long-term follow-up evaluation compared with FAP-only patients ( The difference between groups is significant at P < .05.
likely to meet criteria for a current DSM-IV anxiety disorder and 1.79 (95% CI, Table 3 shows the prevalence of FGIDs at follow-up evaluation by nausea group. Chisquared tests indicated these differences were significant. However, logistic regression analyses controlling for baseline abdominal pain severity did not yield significant group differences in the presence of Rome III diagnoses at follow-up evaluation.
Discussion
This study shows that pediatric patients with FAP and comorbid nausea experience worse abdominal pain, gastrointestinal and extraintestinal somatic symptoms, depression, and functional disability compared with FAP patients without nausea. Moreover, as adolescents and young adults, FAP patients who reported significant nausea at their initial pediatric gastroenterology evaluation reported significantly greater extraintestinal somatic symptoms, depression, and anxiety than those who presented without nausea. In addition, compared with FAP patients without nausea at initial evaluation, those with nausea were more likely to meet the diagnostic criteria for past or current anxiety disorders and a past major depressive episode. This was a prospective cohort study to report the negative long-term symptom and mental health outcomes for pediatric patients with FAP who also complain of nausea.
Previously published work on this patient sample has shown that current and lifetime diagnoses of anxiety disorders are substantially higher in adolescents with a history of FAP compared with healthy controls (lifetime, 51% vs 20%; current, 30% vs 12%). 2 The lifetime risk of depressive disorder is also significantly higher in those with FAP (40% vs 16%), 2 especially those with multiple nonintestinal somatic complaints. 12 In the present study, the subgroup of FAP patients with significant nausea had more depressive symptoms at initial evaluation and more anxiety and depressive disorders at follow-up evaluation than those with FAP alone. These differences persisted when controlling for abdominal pain severity, suggesting that nausea is an independent factor driving the difference between groups. This is in line with previous studies in children with FAP and nausea that found nausea severity to correlate with anxiety and maladaptive coping. 4, 6 Our findings suggest that nausea is an independent risk factor for current and future depression and anxiety in FAP. This may be owing to chronic nausea being a distressing symptom that permeates multiple areas of physical and psychosocial functioning. It may be difficult for these patients to maintain good nutrition, sleep habits, exercise, and resiliency when they frequently are nauseated. Alternatively, FAP patients with comorbid nausea may represent a phenotype with autonomic nervous system dysfunction that contributes to both nausea and emotional distress. Alterations in autonomic nervous system function have been described in patients with both childhood anxiety and chronic nausea. 23, 24 Autonomic nervous system imbalance should be considered as a possible unifying etiology.
This study shows that children with FAP and nausea are more likely than those without nausea to have FGIDs in adulthood. This increased frequency of FGIDs in adulthood did not remain significant when controlling for abdominal pain at baseline, suggesting that the combination of both nausea and abdominal pain severity may increase the risk for persistent FGIDs. Both extraintestinal somatic symptoms and depression have been identified as predictors for future FGIDs in children with FAP. 3 As we report in this study, children with FAP and nausea have a higher burden of somatic symptoms and depression in childhood and young adulthood. These comorbidities may increase the risk for FGIDs. Strengths of this study include its large sample, prospective design, extensive follow-up period, use of validated pediatric questionnaires, and inclusion of psychosocial measures. By including only those patients suffering from "a lot" or "a whole lot" of nausea within the prior 2 weeks, we were able to focus on the most severe phenotype of nausea sufferers. This likely accounts for some of the difference in the prevalence of nausea reported in our study population of children with FAP (45%) than what has been reported previously (53%-59%). 4, 6 There were several limitations to this study. First, although all FAP patients underwent an extensive medical evaluation, the medical evaluation typically did not evaluate 2 secondary conditions that may be associated with nausea. Specifically, no formal screening for postural orthostatic tachycardia syndrome (POTS) was performed. Abdominal pain and recurrent nausea are common among children with POTS and it is known to co-exist with FGIDs. 25, 26 We cannot rule out the possibility that some children may have had POTS and not FAP complicated by nausea. We also did not perform gastric emptying studies in all participants to rule out gastroparesis. These studies were ordered at the discretion of the pediatric gastroenterologist based on patient presentation. Gastroparesis symptoms may be nonspecific in children and can include nausea and abdominal pain. 27, 28 The prevalence of gastroparesis in children is unknown but based on the low adult prevalence of 0.04% to 4%, 29 it is likely that the majority of our cohort would not have had gastroparesis.
Second, we cannot determine the nature of the relationship between FAP and nausea. FAP could contribute to the development of nausea or vice versa. Similarly, anxiety could contribute to the development of nausea or result from experiencing chronic nausea. Prospective studies beginning in early childhood are needed to specifically assess the timing of the development of these disorders.
Finally, baseline nausea was assessed at a time when there were no validated measures for pediatric nausea. The Nausea Profile recently was validated for pediatric assessments; however, this profile does not assess frequency or chronicity.
9,30 The Baxter Retching Faces Scale provides a pediatric-appropriate pictorial scale for nausea severity; however, it has been validated only for acute nausea. 23 Future research should focus on diagnostic tools to better define this patient population and provide a measurement tool for therapeutic trials.
Children with FAP and nausea experience increased morbidity in the short and long term. They are at increased risk for extraintestinal somatic symptoms, anxiety, and depression irrespective of abdominal pain severity. This suggests that nausea is more than just a comorbid symptom of FAP and may have a different underlying etiology necessitating different forms of treatment.
